SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Lindegren Sture 1960) "

Sökning: WFRF:(Lindegren Sture 1960)

  • Resultat 1-10 av 82
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Albertsson, Per, 1964, et al. (författare)
  • Astatine-211 based radionuclide therapy: Current clinical trial landscape
  • 2023
  • Ingår i: Frontiers in Medicine. - : Frontiers Media SA. - 2296-858X. ; 9
  • Tidskriftsartikel (refereegranskat)abstract
    • Astatine-211 (At-211) has physical properties that make it one of the top candidates for use as a radiation source for alpha particle-based radionuclide therapy, also referred to as targeted alpha therapy (TAT). Here, we summarize the main results of the completed clinical trials, further describe ongoing trials, and discuss future prospects.
  •  
2.
  • Andersson, Håkan, 1944, et al. (författare)
  • Astatine-211-labeled antibodies for treatment of disseminated ovarian cancer: an overview of results in an ovarian tumor model
  • 2003
  • Ingår i: Clin Cancer Res. - 1078-0432. ; 9:10 Pt 2
  • Tidskriftsartikel (refereegranskat)abstract
    • PURPOSE: The aim of the study was to establish and refine a preclinical model to alpha-immunoradiotherapy of ovarian cancer. EXPERIMENTAL DESIGN: At-211 was produced by cyclotron irradiation of a bismuth-209 target and isolated using a novel dry distillation procedure. Monoclonal antibodies were radiohalogenated with the intermediate reagent N-succinimidyl 3-(trimethylstannyl)benzoate and characterized in terms of radiochemical yield and in vitro binding properties. In vitro OVCAR-3 cells were irradiated using an external Cobalt-60 beam, as reference, or At-211-albumin and labeled antibody. Growth assays were used to establish cell survival. A Monte Carlo program was developed to simulate the energy imparted and the track length distribution. Nude mice were used for studies of WBC depression, with various activities of Tc-99m antibodies, as reference, and At-211 antibodies. In efficacy studies, OVCAR-3 cells were inoculated i.p., and animals were treated 2 weeks later. The animals were either dissected 6 weeks later or followed-up for long-term survival. RESULTS: A rapid distillation procedure, as well as a rapid and high-yield, single-pot labeling procedure, was achieved. From growth inhibition data, the relative biological effectiveness of the alpha-emission for OVCAR-3 cells was estimated to be approximately 5, which is in the same range as found in vivo for hematological toxicity. At-211 MOv18 was found to effectively inhibit the development of tumors and ascites, also resulting in long-term survival without significant toxic effect. CONCLUSIONS: Use of the short-range, high-linear energy transfer alpha-emitter At-211 conjugated to a surface epitope-recognizing monoclonal antibody appears to be highly efficient without significant toxicity in a mouse peritoneal tumor model, urging a Phase I clinical trial.
  •  
3.
  • Andersson, Håkan, 1944, et al. (författare)
  • Comparison of the therapeutic efficacy of 211At- and 131I-labelled monoclonal antibody MOv18 in nude mice with intraperitoneal growth of human ovarian cancer.
  • 2001
  • Ingår i: Anticancer research. - 0250-7005. ; 21:1A, s. 409-12
  • Tidskriftsartikel (refereegranskat)abstract
    • The purpose of the present study was to compare the therapeutic efficacy of the alpha-emitter Astatine-211 with the beta-emitter Iodine-131 bound to the specific monoclonal antibody MOv18. The measurements were performed in an ovarian cancer cell line (NIH:OVCAR 3) growing intraperitoneally in nude mice. Two weeks after the intraperitoneal inoculation of 1 x 10(7) cells of the human ovarian cancer cell line NIH:OVCAR-3 twenty mice were treated intraperitoneally with the specific monoclonal antibody MOv-18 labelled with either 211At (310-400 kBq) or 131I (5100-6200 kBq). The pharmacokinetics and biodistribution of labelled antibody in tumour-free animals were studied and the resulting bone marrow dose was estimated. When the mice were treated with 211At-labelled antibody 9 out of 10 mice were free of macro- and microscopic tumour compared to 3 out of 10 when Iodine-131 was used. The equivalent dose to the bone marrow was 2.4-3.1 Sv from 211At- and 3.4-4.1 Sv from 131I-irradiation. The therapeutic efficacy of 211At-labelled specific antibody is very good and, at approximately equivalent bone marrow doses, better than that of 131I.
  •  
4.
  • Andersson, Håkan, 1944, et al. (författare)
  • Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients: pharmacokinetics and dosimetry of (211)At-MX35 F(ab')2--a phase I study.
  • 2009
  • Ingår i: Journal of nuclear medicine : official publication, Society of Nuclear Medicine. - : Society of Nuclear Medicine. - 0161-5505. ; 50:7, s. 1153-60
  • Tidskriftsartikel (refereegranskat)abstract
    • The alpha-emitter (211)At labeled to a monoclonal antibody has proven safe and effective in treating microscopic ovarian cancer in the abdominal cavity of mice. Women in complete clinical remission after second-line chemotherapy for recurrent ovarian carcinoma were enrolled in a phase I study. The aim was to determine the pharmacokinetics for assessing absorbed dose to normal tissues and investigating toxicity. METHODS: Nine patients underwent laparoscopy 2-5 d before the therapy; a peritoneal catheter was inserted, and the abdominal cavity was inspected to exclude the presence of macroscopic tumor growth or major adhesions. (211)At was labeled to MX35 F(ab')(2) using the reagent N-succinimidyl-3-(trimethylstannyl)-benzoate. Patients were infused with (211)At-MX35 F(ab')(2) (22.4-101 MBq/L) in dialysis solution via the peritoneal catheter. gamma-Camera scans were acquired on 3-5 occasions after infusion, and a SPECT scan was acquired at 6 h. Samples of blood, urine, and peritoneal fluid were collected at 1-48 h. Hematology and renal and thyroid function were followed for a median of 23 mo. RESULTS: Pharmacokinetics and dosimetric results were related to the initial activity concentration (IC) of the infused solution. The decay-corrected activity concentration decreased with time in the peritoneal fluid to 50% IC at 24 h, increased in serum to 6% IC at 45 h, and increased in the thyroid to 127% +/- 63% IC at 20 h without blocking and less than 20% IC with blocking. No other organ uptakes could be detected. The cumulative urinary excretion was 40 kBq/(MBq/L) at 24 h. The estimated absorbed dose to the peritoneum was 15.6 +/- 1.0 mGy/(MBq/L), to red bone marrow it was 0.14 +/- 0.04 mGy/(MBq/L), to the urinary bladder wall it was 0.77 +/- 0.19 mGy/(MBq/L), to the unblocked thyroid it was 24.7 +/- 11.1 mGy/(MBq/L), and to the blocked thyroid it was 1.4 +/- 1.6 mGy/(MBq/L) (mean +/- SD). No adverse effects were observed either subjectively or in laboratory parameters. CONCLUSION: This study indicates that by intraperitoneal administration of (211)At-MX35 F(ab')(2) it is possible to achieve therapeutic absorbed doses in microscopic tumor clusters without significant toxicity.
  •  
5.
  • Aneheim, Emma, 1982, et al. (författare)
  • Astatine-211 labeling: a study towards automatic production of astatinated antibodies
  • 2015
  • Ingår i: Journal of Radioanalytical and Nuclear Chemistry. - : Springer Science and Business Media LLC. - 0236-5731 .- 1588-2780. ; 303:1, s. 979-983
  • Tidskriftsartikel (refereegranskat)abstract
    • Targeted alpha therapy is especially interesting for therapy of microscopic cancer tumors due to short path length and high linear energy transfer of the alpha particles. One of the most promising nuclides for targeted alpha therapy is At-211. To facilitate larger clinical studies using At-211, the current manual synthesis of radiolabeled antibodies would benefit from being transferred into an automated method. In this work, successful modifications of the manual synthesis have been performed in order to adapt it to automation. The automatic synthesis has also been tested using the modified synthesis method.
  •  
6.
  • Aneheim, Emma, 1982, et al. (författare)
  • Automated astatination of biomolecules--a stepping stone towards multicenter clinical trials.
  • 2015
  • Ingår i: Scientific reports. - : Springer Science and Business Media LLC. - 2045-2322. ; 5
  • Tidskriftsartikel (refereegranskat)abstract
    • To facilitate multicentre clinical studies on targeted alpha therapy, it is necessary to develop an automated, on-site procedure for conjugating rare, short-lived, alpha-emitting radionuclides to biomolecules. Astatine-211 is one of the few alpha-emitting nuclides with appropriate chemical and physical properties for use in targeted therapies for cancer. Due to the very short range of the emitted α-particles, this therapy is particularly suited to treating occult, disseminated cancers. Astatine is not intrinsically tumour-specific; therefore, it requires an appropriate tumour-specific targeting vector, which can guide the radiation to the cancer cells. Consequently, an appropriate method is required for coupling the nuclide to the vector. To increase the availability of astatine-211 radiopharmaceuticals for targeted alpha therapy, their production should be automated. Here, we present a method that combines dry distillation of astatine-211 and a synthesis module for producing radiopharmaceuticals into a process platform. This platform will standardize production of astatinated radiopharmaceuticals, and hence, it will facilitate large clinical studies focused on this promising, but chemically challenging, alpha-emitting radionuclide. In this work, we describe the process platform, and we demonstrate the production of both astaine-211, for preclinical use, and astatine-211 labelled antibodies.
  •  
7.
  • Aneheim, Emma, 1982, et al. (författare)
  • N-[2-(maleimido)ethyl]-3-(trimethylstannyl)benzamide, a molecule for radiohalogenation of proteins and peptides
  • 2015
  • Ingår i: Applied Radiation and Isotopes. - : Elsevier BV. - 0969-8043 .- 1872-9800. ; 96, s. 1-5
  • Tidskriftsartikel (refereegranskat)abstract
    • In this work a new coupling reagent, N[2-(maleimido)ethyl]-3-(trimethylstannyl)benzamide, for radiohalogenation has been synthesized and characterized. The reagent is intended to either be attached to reduced disulfide bridges of proteins (making the halogenation site-specific) or to free terminal cysteine groups on peptides. The new reagent was also shown to be easily halogenated with inactive bromine and iodine as well as I-125 and At-211, indicating potential use within targeted radiotherapy.
  •  
8.
  • Aneheim, Emma, 1982, et al. (författare)
  • Shelf-Life of e-Lysyl-3-(Trimethylstannyl)Benzamide Immunoconjugates, Precursors for At-211 Labeling of Antibodies
  • 2015
  • Ingår i: Cancer Biotherapy and Radiopharmaceuticals. - : Mary Ann Liebert Inc. - 1084-9785 .- 1557-8852. ; 30:1, s. 41-45
  • Tidskriftsartikel (refereegranskat)abstract
    • Astatine-211 is possibly the most promising radionuclide for targeted alpha-particle therapy when it comes to the treatment of occult disseminated cancer. Preclinical research has proven effective, and patient studies have been initiated based on these results. However, a lack of production capacity and the complex radiochemistry of At-211 are major obstacles for research and prospective clinical applications. In the present study, astatination of immunoconjugates, already prepared well in advance before radiolabeling, was performed to investigate the possibility of formulating a kit-like reagent for the production of At-211 radiopharmaceuticals. The shelf-life of e-lysyl-3-(trimethylstannyl)benzamide immunoconjugates was evaluated, that is, the effect of different storage times on the quality of the immunoconjugates. The quality being referred to is the capacity to maintain a good radiochemical yield and good cell-binding property after labeling with At-211. The stability of the conjugates was found to be pH dependent with high stability at pH >= 7 and less stability at pH <= 5.5. The immunoconjugates (based on trastuzumab) could be kept for more than 3 months in a phosphate buffered saline solution (pH 7.4) at 4 degrees C before labeling, without compromising the quality of the labeled product. The conjugates are also unaffected by storage at -20 degrees C. Conjugates with a good shelf-life compatible with distant shipping as well as improved radiochemistry are important steps to facilitate further clinical progress with At-211.
  •  
9.
  • Aneheim, Emma, 1982, et al. (författare)
  • Synthesis and Evaluation of Astatinated N-[2-(Maleimido)ethyl]-3-(trimethylstannyl)benzamide Immunoconjugates
  • 2016
  • Ingår i: Bioconjugate chemistry. - : American Chemical Society (ACS). - 1520-4812 .- 1043-1802. ; 27:3, s. 688-97
  • Tidskriftsartikel (refereegranskat)abstract
    • Effective treatment of metastasis is a great challenge in the treatment of different types of cancers. Targeted alpha therapy utilizes the short tissue range (50-100 μm) of α particles, making the method suitable for treatment of disseminated occult cancers in the form of microtumors or even single cancer cells. A promising radioactive nuclide for this type of therapy is astatine-211. Astatine-211 attached to tumor-specific antibodies as carrier molecules is a system currently under investigation for use in targeted alpha therapy. In the common radiolabeling procedure, astatine is coupled to the antibody arbitrarily on lysine residues. By instead coupling astatine to disulfide bridges in the antibody structure, the immunoreactivity of the antibody conjugates could possibly be increased. Here, the disulfide-based conjugation was performed using a new coupling reagent, maleimidoethyl 3-(trimethylstannyl)benzamide (MSB), and evaluated for chemical stability in vitro. The immunoconjugates were subsequently astatinated, resulting in both high radiochemical yield and high specific activity. The MSB-conjugate was shown to be stable with a long shelf life prior to the astatination. In a comparison of the in vivo distribution of the new immunoconjugate with other tin-based immunoconjugates in tumor-bearing mice, the MSB conjugation method was found to be a viable option for successful astatine labeling of different monoclonal antibodies.
  •  
10.
  • Aneheim, Emma, 1982, et al. (författare)
  • Towards elucidating the radiochemistry of astatine - Behavior in chloroform
  • 2019
  • Ingår i: Scientific Reports. - : Springer Science and Business Media LLC. - 2045-2322. ; 9
  • Tidskriftsartikel (refereegranskat)abstract
    • Targeted alpha therapy of disseminated cancer is an emerging technique where astatine-211 is one of the most promising candidate nuclides. Although astatine has been known for over 70 years, its chemistry is still largely unexplored, mainly due to the lack of stable or long-lived isotopes. However, substantial amounts of astatine-211 can be produced in cyclotrons by the bombardment of natural bismuth. The astatine can be recovered from the resulting irradiated target material through either wet extraction or dry-distillation. Chloroform has become an important intermediate solvent for the recovery of astatine after production, especially following dry distillation. In this work, the radiochemistry of astatine in chloroform was investigated using evaporation, solvent extraction, chromatographic methods and molecular modeling. The extraction of astatine in chloroform led to the formation of multiple astatine species, allowing for evaporation of the solvent to dryness without any loss of activity. Radiolysis products of chloroform were shown to play an important role in the speciation of astatine forming both reactive and kinetically stable compounds. It was hypothesized that reactions with chlorine, as well as trichloromethyl hydroperoxide, forming polar astatine compounds are important reactions under the current experimental conditions.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 82
Typ av publikation
tidskriftsartikel (59)
konferensbidrag (20)
bokkapitel (2)
doktorsavhandling (1)
Typ av innehåll
refereegranskat (59)
övrigt vetenskapligt/konstnärligt (23)
Författare/redaktör
Lindegren, Sture, 19 ... (82)
Bäck, Tom, 1964 (60)
Palm, Stig, 1964 (52)
Jacobsson, Lars, 194 ... (45)
Hultborn, Ragnar, 19 ... (42)
Jensen, Holger (36)
visa fler...
Albertsson, Per, 196 ... (33)
Andersson, Håkan, 19 ... (23)
Elgqvist, Jörgen, 19 ... (22)
Aneheim, Emma, 1982 (18)
Jensen, H. (17)
Karlsson, Börje (9)
Warnhammar Finnborg, ... (8)
Horvath, György, 194 ... (7)
Hallqvist, Andreas, ... (5)
Johansson, Mia, 1977 (5)
Cederkrantz, Elin (5)
Bernhardt, Peter, 19 ... (4)
Bergmark, Karin, 196 ... (3)
Johansson, Bengt R, ... (3)
Haraldsson, Börje, 1 ... (3)
Himmelman, Jakob (3)
Dahm-Kähler, Pernill ... (2)
Timperanza, Chiara (2)
Gustafsson, Anna (2)
Tennvall, Jan (2)
Zimmermann, T. (1)
Foreman, Mark, 1973 (1)
Albertsson, Per (1)
Jacobsson, Lars (1)
Damber, Jan-Erik, 19 ... (1)
Holmberg, Erik, 1951 (1)
Karlsson, Per, 1963 (1)
Ljungberg, Michael (1)
Svedhem, Sofia, 1970 (1)
Ekberg, Christian, 1 ... (1)
Danielsson, Anna, 19 ... (1)
Ahlberg, Daniel, 198 ... (1)
Gedda, Lars (1)
Skarnemark, Gunnar, ... (1)
Smerud, K. (1)
Holgersson, Stellan, ... (1)
Angenete, Eva, 1972 (1)
Johansson, Martin E, ... (1)
Backhaus, Thomas, 19 ... (1)
Leser, Gunilla (1)
Divgi, Chaitanya (1)
Swanpalmer, John, 19 ... (1)
Halleröd, Jenny, 198 ... (1)
Falk, Peter, 1962 (1)
visa färre...
Lärosäte
Göteborgs universitet (81)
Chalmers tekniska högskola (13)
Lunds universitet (3)
Uppsala universitet (1)
Språk
Engelska (82)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (79)
Naturvetenskap (6)
Teknik (1)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy